Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Seed CoTSE:7743 +18.69%71 Debt-to-EBITDA is 5.57 as of Jun. 2026, which is 9% above its 10-year median of 5.13. GuruFocus rates TSE:7743 with a GF Score™ of 71/100 and a GF Value™ of 円538.80 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 477 Medical Devices & Instruments companies, Seed Co ranks worse than 89.31% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Seed Co's Debt-to-EBITDA or its related term are showing as below:
TSE:7743'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 4.45 Med: 5.13 Max: 7.42
Current: 7.23
During the past 13 years, the highest Debt-to-EBITDA Ratio of Seed Co was 7.42. The lowest was 4.45. And the median was 5.13.
TSE:7743's Debt-to-EBITDA is ranked worse than 89.31% of 477
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs TSE:7743: 7.23
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Seed Co Debt-to-EBITDA Related Terms
Seed Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Seed Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7743 vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Seed Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seed Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Seed Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Seed Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Seed Co (TSE:7743) has a Debt-to-EBITDA of 5.57 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Seed Co. This is near median its historical median of 5.13. Over the past decade, Seed Co's Debt-to-EBITDA has ranged from 4.45 to 7.42. According to the industry distribution chart, Seed Co ranks #426 out of 477 companies in the Medical Devices & Instruments industry, placing it in the top 89.3%.
Is Seed Co's Debt-to-EBITDA too high?
Seed Co's current Debt-to-EBITDA of 5.57 is near median its 10-year median of 5.13. Over the past 10 years, this metric has ranged from a low of 4.45 to a high of 7.42. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.61. Seed Co's value of 5.57 is 246% above this industry median. Based on the distribution chart, Seed Co ranks #426 out of 477 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Seed Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Seed Co's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Seed Co ranks #426 out of 477 companies for Debt-to-EBITDA. This places Seed Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.61. Seed Co's value of 5.57 is 246% above this benchmark. Historically, Seed Co's own Debt-to-EBITDA has ranged from 4.45 to 7.42 over the past decade. While the company's 10-year median is 5.13 vs. the industry median of 1.61, Seed Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.61, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seed Co's current Debt-to-EBITDA of 5.57 is 246% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Seed Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seed Co's current Debt-to-EBITDA is 5.57, which is near median its own 10-year median of 5.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seed Co stock overvalued right now?
Based on GuruFocus' analysis, Seed Co (TSE:7743) is currently considered Modestly Overvalued. The stock's GF Value™ is 円538.80, compared to a current price of 円635.00 — trading 17.9% above its estimated fair value. The current Debt-to-EBITDA is 5.57, which is near median its 10-year median of 5.13 and 246% above the Medical Devices & Instruments industry median of 1.61. Seed Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Seed Co (TSE:7743), the current Debt-to-EBITDA is 5.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seed Co (TSE:7743) Overvalued in 2026?
Based on GuruFocus' analysis, Seed Co stock appears to be overvalued.
The current stock price of 円635.00 is trading 17.9% above its estimated GF Value™ of 円538.80.
GuruFocus considers Seed Co to be Modestly Overvalued.
Key valuation signals for TSE:7743:
Debt-to-EBITDA: 5.57 (near median its 10-year median of 5.13)
GF Value™: 円538.80 vs. price of 円635.00 (17.9% above fair value)
Industry Position: 246% above the Medical Devices & Instruments median (#426 of 477)
No single metric tells the full story. See the TSE:7743 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seed Co Ltd is engaged in the manufacturing and sells of contact lenses, glasses frames, and other eye care products in Japan. Its main products include SEED 1dayPure daily disposable lenses, SEED Fine disposable lenses, SEED S-1 high oxygen permeability hard contact lenses.
71GF Score
Get the complete analysis for TSE:7743
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7743 has been successfully added to your 
